AstraZeneca (AZN) to Release Quarterly Earnings on Thursday

AstraZeneca (NASDAQ:AZN) is expected to issue its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of $1.14 per share and revenue of $14.7544 billion for the quarter. Parties can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Thursday, November 6, 2025 at 8:00 AM ET.

AstraZeneca Price Performance

AstraZeneca stock opened at $82.03 on Wednesday. The stock has a market cap of $254.41 billion, a P/E ratio of 30.84, a price-to-earnings-growth ratio of 1.52 and a beta of 0.36. The company has a fifty day simple moving average of $81.21 and a 200-day simple moving average of $75.28. AstraZeneca has a 12-month low of $61.24 and a 12-month high of $86.57. The company has a current ratio of 0.86, a quick ratio of 0.67 and a debt-to-equity ratio of 0.55.

Institutional Investors Weigh In On AstraZeneca

A number of institutional investors and hedge funds have recently made changes to their positions in AZN. Transamerica Financial Advisors LLC raised its holdings in shares of AstraZeneca by 86.1% in the second quarter. Transamerica Financial Advisors LLC now owns 1,647 shares of the company’s stock valued at $115,000 after buying an additional 762 shares during the last quarter. Rakuten Securities Inc. raised its holdings in shares of AstraZeneca by 30.2% in the second quarter. Rakuten Securities Inc. now owns 1,969 shares of the company’s stock valued at $138,000 after buying an additional 457 shares during the last quarter. Great Valley Advisor Group Inc. raised its holdings in shares of AstraZeneca by 24.0% in the second quarter. Great Valley Advisor Group Inc. now owns 4,949 shares of the company’s stock valued at $346,000 after buying an additional 957 shares during the last quarter. Glenview Trust co raised its holdings in shares of AstraZeneca by 17.6% in the second quarter. Glenview Trust co now owns 5,107 shares of the company’s stock valued at $357,000 after buying an additional 765 shares during the last quarter. Finally, Brighton Jones LLC raised its holdings in shares of AstraZeneca by 93.2% in the fourth quarter. Brighton Jones LLC now owns 5,782 shares of the company’s stock valued at $379,000 after buying an additional 2,789 shares during the last quarter. 20.35% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

AZN has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a “buy (b)” rating on shares of AstraZeneca in a research report on Wednesday, October 8th. Berenberg Bank set a $97.00 price target on shares of AstraZeneca in a research note on Wednesday, July 9th. Jefferies Financial Group initiated coverage on shares of AstraZeneca in a research note on Monday, October 27th. They set a “buy” rating on the stock. Finally, Deutsche Bank Aktiengesellschaft lowered shares of AstraZeneca from a “hold” rating to a “sell” rating in a research note on Thursday, October 16th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, AstraZeneca has a consensus rating of “Moderate Buy” and an average price target of $86.00.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.